113 related articles for article (PubMed ID: 21982494)
21. The cleavage of biglycan by aggrecanases.
Melching LI; Fisher WD; Lee ER; Mort JS; Roughley PJ
Osteoarthritis Cartilage; 2006 Nov; 14(11):1147-54. PubMed ID: 16806997
[TBL] [Abstract][Full Text] [Related]
22. Structure-activity relationships and pharmacokinetic analysis for a series of potent, systemically available biphenylsulfonamide matrix metalloproteinase inhibitors.
O'Brien PM; Ortwine DF; Pavlovsky AG; Picard JA; Sliskovic DR; Roth BD; Dyer RD; Johnson LL; Man CF; Hallak H
J Med Chem; 2000 Jan; 43(2):156-66. PubMed ID: 10649971
[TBL] [Abstract][Full Text] [Related]
23. MMP proteolysis of the human extracellular matrix protein aggrecan is mainly a process of normal turnover.
Struglics A; Hansson M
Biochem J; 2012 Sep; 446(2):213-23. PubMed ID: 22670872
[TBL] [Abstract][Full Text] [Related]
24. An aggrecanase and osteoarthritis.
Karsenty G
N Engl J Med; 2005 Aug; 353(5):522-3. PubMed ID: 16079379
[No Abstract] [Full Text] [Related]
25. Effects of RNAi-mediated inhibition of aggrecanase-1 and aggrecanase-2 on rat costochondral chondrocytes in vitro.
Wang ZH; Yang ZQ; He XJ; Wang L; Li LX; Tu JB
Acta Pharmacol Sin; 2008 Oct; 29(10):1215-26. PubMed ID: 18817627
[TBL] [Abstract][Full Text] [Related]
26. Aggrecanase- and matrix metalloproteinase-mediated aggrecan degradation is associated with different molecular characteristics of aggrecan and separated in time ex vivo.
Madsen SH; Sumer EU; Bay-Jensen AC; Sondergaard BC; Qvist P; Karsdal MA
Biomarkers; 2010 May; 15(3):266-76. PubMed ID: 20039789
[TBL] [Abstract][Full Text] [Related]
27. [Effects of RNA interference against aggrecanase 1 gene on extracellular matrix metabolism of cultured chondrocytes in vitro].
Wang ZH; He XJ; Yang ZQ; Wang L; Li LX; Tu JB
Nan Fang Yi Ke Da Xue Xue Bao; 2009 Sep; 29(9):1766-9. PubMed ID: 19778785
[TBL] [Abstract][Full Text] [Related]
28. Discovery of potent, selective, and orally active carboxylic acid based inhibitors of matrix metalloproteinase-13.
Monovich LG; Tommasi RA; Fujimoto RA; Blancuzzi V; Clark K; Cornell WD; Doti R; Doughty J; Fang J; Farley D; Fitt J; Ganu V; Goldberg R; Goldstein R; Lavoie S; Kulathila R; Macchia W; Parker DT; Melton R; O'Byrne E; Pastor G; Pellas T; Quadros E; Reel N; Roland DM; Sakane Y; Singh H; Skiles J; Somers J; Toscano K; Wigg A; Zhou S; Zhu L; Shieh WC; Xue S; McQuire LW
J Med Chem; 2009 Jun; 52(11):3523-38. PubMed ID: 19422229
[TBL] [Abstract][Full Text] [Related]
29. Analysis of ADAMTS4 and MT4-MMP indicates that both are involved in aggrecanolysis in interleukin-1-treated bovine cartilage.
Patwari P; Gao G; Lee JH; Grodzinsky AJ; Sandy JD
Osteoarthritis Cartilage; 2005 Apr; 13(4):269-77. PubMed ID: 15780640
[TBL] [Abstract][Full Text] [Related]
30. ADAMTS-4 and ADAMTS-5: key enzymes in osteoarthritis.
Verma P; Dalal K
J Cell Biochem; 2011 Dec; 112(12):3507-14. PubMed ID: 21815191
[TBL] [Abstract][Full Text] [Related]
31. Molecular docking and dynamics simulation study on the influence of Zn2+ on the binding modes of aggrecanase with its inhibitors.
Suganya PS; Kalva S; Saleena LM
Comb Chem High Throughput Screen; 2014; 17(10):891-903. PubMed ID: 25386707
[TBL] [Abstract][Full Text] [Related]
32. 5-((1H-pyrazol-4-yl)methylene)-2-thioxothiazolidin-4-one inhibitors of ADAMTS-5.
Gilbert AM; Bursavich MG; Lombardi S; Georgiadis KE; Reifenberg E; Flannery CR; Morris EA
Bioorg Med Chem Lett; 2007 Mar; 17(5):1189-92. PubMed ID: 17210252
[TBL] [Abstract][Full Text] [Related]
33. N-O-isopropyl sulfonamido-based hydroxamates: design, synthesis and biological evaluation of selective matrix metalloproteinase-13 inhibitors as potential therapeutic agents for osteoarthritis.
Nuti E; Casalini F; Avramova SI; Santamaria S; Cercignani G; Marinelli L; La Pietra V; Novellino E; Orlandini E; Nencetti S; Tuccinardi T; Martinelli A; Lim NH; Visse R; Nagase H; Rossello A
J Med Chem; 2009 Aug; 52(15):4757-73. PubMed ID: 19606871
[TBL] [Abstract][Full Text] [Related]
34. Identifying the human aggrecanase.
Fosang AJ; Rogerson FM
Osteoarthritis Cartilage; 2010 Sep; 18(9):1109-16. PubMed ID: 20633677
[TBL] [Abstract][Full Text] [Related]
35. CCAAT/enhancer binding protein β regulates expression of matrix metalloproteinase-3 in arthritis.
Tsushima H; Okazaki K; Hayashida M; Ushijima T; Iwamoto Y
Ann Rheum Dis; 2012 Jan; 71(1):99-107. PubMed ID: 21917825
[TBL] [Abstract][Full Text] [Related]
36. Spingosine-1-phosphate stimulates proliferation and counteracts interleukin-1 induced nitric oxide formation in articular chondrocytes.
Stradner MH; Hermann J; Angerer H; Setznagl D; Sunk I-; Windhager R; Graninger WB
Osteoarthritis Cartilage; 2008 Mar; 16(3):305-11. PubMed ID: 17703957
[TBL] [Abstract][Full Text] [Related]
37. Effects of transforming growth factor-beta on aggrecanase production and proteoglycan degradation by human chondrocytes in vitro.
Moulharat N; Lesur C; Thomas M; Rolland-Valognes G; Pastoureau P; Anract P; De Ceuninck F; Sabatini M
Osteoarthritis Cartilage; 2004 Apr; 12(4):296-305. PubMed ID: 15023381
[TBL] [Abstract][Full Text] [Related]
38. The role of ADAM-TS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) in a model of cartilage degradation.
Tortorella MD; Malfait AM; Deccico C; Arner E
Osteoarthritis Cartilage; 2001 Aug; 9(6):539-52. PubMed ID: 11520168
[TBL] [Abstract][Full Text] [Related]
39. Differential regulation of matrix degrading enzymes in a TNFalpha-induced model of nucleus pulposus tissue degeneration.
Séguin CA; Bojarski M; Pilliar RM; Roughley PJ; Kandel RA
Matrix Biol; 2006 Sep; 25(7):409-18. PubMed ID: 16934445
[TBL] [Abstract][Full Text] [Related]
40. The amelioration of cartilage degeneration by ADAMTS-5 inhibitor delivered in a hyaluronic acid hydrogel.
Chen P; Zhu S; Wang Y; Mu Q; Wu Y; Xia Q; Zhang X; Sun H; Tao J; Hu H; Lu P; Ouyang H
Biomaterials; 2014 Mar; 35(9):2827-36. PubMed ID: 24424207
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
